

您的位置: [首页](#)>> [文章摘要](#)
[中文](#) [English](#)

CD133表达与肺癌患者临床病理特征相关性的Meta分析

谈瑶曦, 陈波, 许伟, 吴剑卿

210029 南京医科大学第一附属医院老年医学科

吴剑卿, Email: jwuny@njmu.edu.cn

国家自然科学基金(30971320)

摘要:目的 通过Meta分析的方法综合评价CD133与肺癌患者临床病理特征关系。方法 检索CNKI, 纳入公开发表涉及CD133表达与肺癌临床病理特征的中英文文献, 使用StatView 10.0.2.0000进行分析。结果 共获取文献15篇(英文7篇、中文8篇), 1102例患者。Meta分析显示III期之间无显著性差异(pooled OR=0.782, 95% CI=0.435~1.406, P=0.411)。CD133表达与肺癌低分化相关(pooled OR=0.97, 95% CI=0.71~1.33, P=0.86)。CD133表达在肺癌低分化与高分化之间无显著性差异(OR=1.66, 95% CI=1.15~2.40, P=0.006); CD133表达在肺癌淋巴结转移与非淋巴结转移之间无显著性差异(OR=2.98, 95% CI=2.04~4.35, P<0.001)。结论 CD133阳性与肺癌组织低分化相关。

关键词: 肺肿瘤; 肿瘤干细胞; Meta分析; CD133

文献标引: 谈瑶曦, 陈波, 许伟, 吴剑卿. CD133表达与肺癌患者临床病理特征相关性的Meta分析. 中华临床医师杂志(电子版), 2013, 7(15): 7074-7078. [复制](#)

参考文献:

- [1] Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin, 2011, 61(5): 9-26.
- [2] Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP guidelines(2nd edition). Chest, 2007, 132: 29S-55S.
- [3] Dontu G, Liu S, Wicha MS. Stem cells in mammary development and prevention and treatment. Stem Cell Rev, 2005, 1: 207-213.
- [4] Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer: the stem cell hypothesis. J Clin Pharmacol, 2005, 45: 872-877.
- [5] Toyooka S, Mitsudomi T, Soh J, et al. Molecular oncology of lung cancer. J Clin Oncol, 2005, 23: 2127-2140.

期刊导读

7卷17期 2013年9月 [最新]



期刊存档

期刊存档

[查看目录](#)

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

编委会

期刊服务



建议我们



会员服务



广告合作



继续教育

[6] Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell population in human colorectal tumors. *Cancer Res*, 2003, 63: 5821-5828.

[7] Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ as cancer stem/progenitor cells. *Biochem Biophys Res Commun*, 2006, 351: 105-110.

[8] Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133 in human endometrial cancer. *Int J Gynecol Cancer*, 2008, 18: 506-514.

[9] Kojima M, Ishii G, Atsumi N, et al. Immunohistochemical detection of cancer stem cells in colorectal cancer: a clinicopathological study. *Cancer Sci*, 2008, 99: 105-110.

[10] Eramo A, Lotti F, Sette G, et al. Identification and expansion of a primitive tumor stem cell population. *Cell Death Differ*, 2008, 15: 504-514.

[11] Janikova M, Skarda J, Dziechciarkova M, et al. Identification of cancer stem cells in non-small cell lung cancer. *Biomed Pap Med Fac Univ Palac* 154: 321-326.

[12] Cui F, Wang J, Chen D, et al. CD133 is a temporary marker of cancer stem cells in lung cancer, but not in non-small cell lung cancer. *Oncol Rep*, 2011, 25: 105-110.

[13] Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer stem cells: isolation, characterization, and role in tumor progression. *Proc Natl Acad Sci* 105: 1435-1440.

[14] 徐跃华, 汪家敏, 张光波, 等. CD133和B7-H4在非小细胞肺癌中的表达及意义. *中国肺癌杂志*, 2011, 14(12): 412-415.

[15] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for survival data. *Biometrics*, 1994, 50: 1088-1101.

[16] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple graphical test. *BMJ*, 1997, 315: 629-634.

[17] Cortes-Dericks L, Galetta D, Spaggiari L, et al. High expression of the transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly predicts poor prognosis in lung adenocarcinoma resulting in shorter disease-free interval. *Int J Cancer*, 2012, 111: 173-181.

[18] Herpel E, Jensen K, Muley T, et al. The cancer stem cell antigens CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. *Anticancer Res*, 2011, 31: 4491-4500.

[19] Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the characterization of tumour-initiating cells in non-small-cell lung cancer. *Int J Cancer*, 2009, 124: 446-453.

- [20] Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of ca non-small cell lung cancer patients treated with induction chemoradioth 162-167.
- [21] Salnikov AV, Gladkikh J, Moldenhauer G, et al. CD133 is indica but does not represent a prognostic marker for survival of non-small ce Cancer, 2010, 126: 950-958.
- [22] Li F, Zeng H, Ying K. The combination of stem cell markers CD1 stage I non-small cell lung carcinomas. Med Oncol, 2011, 28: 1458-1462.
- [23] 魏益平, 王梅, 华平, 等. 肿瘤干细胞标志物CD133在非小细胞肺癌中自 学科学版, 2008, 29: 312-316.
- [24] 李红, 王艳, 余莉, 等. 肺神经内分泌癌CD133蛋白表达临床病理意义自 18: 29-31.
- [25] 姚杰, 王志刚, 童文先, 等. 肿瘤干细胞标记物CD133和CD44在肺癌原发 国防医药, 2010, 20: 1300-1303.
- [26] 林旭勇, 刘树立, 刘楠, 等. 干细胞标记物CK19、Notch3、CD133、P75 达及意义. 中国肺癌杂志, 2009, 12: 316-321.
- [27] 顾永平, 孙茂民, 顾丽琴, 等. 肿瘤干细胞标志物CD133、ABCG2、p75~ 其生物学意义. 苏州大学学报:医学版, 2010, 30: 513-516.